Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 29, 2026Journal of Clinical Oncology

A phase 1a/b study of RGT-61159, an oral MYB splicing modulator, in patients with advanced adenoid cystic carcinoma and colorectal cancer.

View Full Paper
Ask AI
Bookmark
Share

Authors

AHAlan L. HoEGEnrique Sanz GarciaRFRenata Ferrarotto

Discussion

Loading...

Member takes

Overview

Randomized trial evaluates safety and efficacy of RGT-61159 in advanced adenoid cystic carcinoma and colorectal cancer, suggesting potential benefits.

Key Points

  • This study aims to evaluate the safety, tolerability, and preliminary anti-tumor activity of RGT-61159 in patients with advanced cancers.
  • Phase 1a/b, multi-center, open-label clinical trial
  • Evaluated RGT-61159 in patients with advanced, relapsed or refractory adenoid cystic carcinoma or colorectal cancer
  • 3+3 dose-escalation design starting at 6 mg with up to 144 mg in 21-day cycles.
  • 44 patients treated with 86% having adenoid cystic carcinoma; significant anti-tumor activity noted.
  • 18 of 35 evaluable patients had tumor regressions; 2 partial responses observed in advanced ACC cases.
  • Robust MYB knockdown (up to 75%) and overall good tolerability at or below RP2D of 84 mg.

Cite This Study

Ho et al. (2026) studied this question.

synapsesocial.com/papers/6a192e95fab5b468c4417b77https://doi.org/10.1200/jco.2026.44.16_suppl.3089
View Full Paper
Ask AI
Bookmark
Share